Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial

Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). METHODS: In CREDENCE (Canaglifl...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Circulation
Główni autorzy: Mahaffey, Kenneth W., Jardine, Meg J., Bompoint, Severine, Cannon, Christopher P., Neal, Bruce, Heerspink, Hiddo J.L., Charytan, David M., Edwards, Robert, Agarwal, Rajiv, Bakris, George, Bull, Scott, Capuano, George, de Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Sun, Tao, Wheeler, David C., Yavin, Yshai, Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Brenner, Barry M., Perkovic, Vlado
Format: Artigo
Język:Inglês
Wydane: Lippincott Williams & Wilkins 2019
Hasła przedmiotowe:
Original Research Articles
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6727954/
https://ncbi.nlm.nih.gov/pubmed/31291786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy